Ellen Rohde
Corporate Officer/Principal at VERVE THERAPEUTICS, INC.
Profile
Ellen Rohde is currently the VP-Preclinical Pharmacology & Toxicology at Verve Therapeutics, Inc. She previously worked as an Associate Director at Biogen, Inc., Director-Analytical Chemistry & DMPK at Cerulean Pharma, Inc., and Senior Director-Pharmacokinetics at Intellia Therapeutics,.
Inc. Rohde holds a doctorate degree from the University of Cincinnati (Ohio) and a graduate degree from Universität Leipzig.
Ellen Rohde active positions
| Companies | Position | Start |
|---|---|---|
| VERVE THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-09-30 |
Former positions of Ellen Rohde
| Companies | Position | End |
|---|---|---|
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
| BIOGEN INC. | Corporate Officer/Principal | - |
| INTELLIA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Ellen Rohde
| University of Cincinnati (Ohio) | Doctorate Degree |
| Universität Leipzig | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BIOGEN INC. | Health Technology |
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| VERVE THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Ellen Rohde
